September 12th, 2012
FDA Rebukes Lancôme on Marketing
By JENNIFER CORBETT DOOREN And EMILY GLAZER
Wall Street Journal
U.S. regulators warned French cosmetics giant L’Oréal SA OR.FR -1.21% that it had gone too far with claims about several pricey antiwrinkle products, and said sales could be halted if the company doesn’t tone them down.
In a letter to L’Oréal’s Lancôme USA subsidiary, the Food and Drug Administration pointed to marketing claims including the assertion that one product “boosts the activity of genes and stimulates the production of youth proteins.”
The suggestion that the products are meant to affect the way the human body works would require them to be classified as new drugs, which would need FDA approval, the agency said.